II. Background
- Pregnancy Categories will be replaced on medication bottles with specific warnings and precautions by 2020 in U.S.
- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425317.htm
- Although FDA Pregnancy Categories are no longer listed, they are included here
- As of 2018, succinct guidance (to replace ABCDX) on specific drugs in pregnancy is lacking
III. Preparations: Upper Respiratory Medications
- See Upper Respiratory Medications in Pregnancy
- First-generation Antihistamines (Sedating Antihistamines)
- Diphenhydramine (Benadryl)
- FDA Category B
- Crosses placenta
- Risk of Oxytocin-like effects at high dose
- Brompheniramine
- FDA Category C
- Chlorpheniramine
- FDA Category C
- Considered as a first-choice Sedating Antihistamine in pregnancy
- Pheniramine
- FDA Category C
- Diphenhydramine (Benadryl)
- Second-generation Antihistamines (Non-Sedating Antihistamines)
- Cetirizine (Zyrtec)
- FDA Category B
- Loratadine (Claritin)
- FDA Category B
- Fexofenadine (Allegra)
- FDA Category C
- Cetirizine (Zyrtec)
-
Decongestants
- Phenylephrine
- FDA Category C
- Crosses placenta (avoid in first trimester)
- Pseudoephedrine
- FDA Category C
- Associated with Gastroschisis, small Intestinal Atresia and hemifacial microsomia (avoid in first trimester)
- Phenylephrine
- Expectorants
- Guaifenesin
- FDA Category C
- No safety data available (avoid in first trimester)
- Guaifenesin
-
Cough Suppressants
- Dextromethorphan
- FDA Category C
- Dextromethorphan
IV. Preparations: Analgesics and antipyretics
-
Acetaminophen
- Crosses the placenta
- FDA Category B (first-choice agent)
-
Aspirin
- Crosses the placenta
- Avoid in pregnancy overall unless specifically indicated (e.g. Preeclampsia Prevention)
- FDA Category C in first and second trimester
- FDA Category D in third trimester (avoid)
-
NSAIDS (Naproxen, Ibuprofen)
- Crosses the placenta
- Avoid in first trimester due to risk of orofacial clefts (Naproxen), cardiac defects and Transposition of the Great Vessels
- FDA Category C in first and second trimester
- FDA Category D in third trimester (avoid due to premature ductus arteriosus closure and oligohydramnios risk)
V. Preparations: Gastrointestinal medications
-
Antacids
- Cimetidine (Tagamet)
- FDA Category B
- Crosses the placenta
- Weak Androgenic Activity in animal studies
- Zantac may be preferred for longerterm use
- Famotidine (Pepcid)
- FDA Category B (based on limited human data)
- Crosses the placenta
- Nizatidine (Axid)
- Crosses the placenta
- Avoid in pregnancy
- Risk of IUGR, fetal death and abortion seen in rabbit studies
- Ranitidine (Zantac)
- FDA Category B
- Crosses the placenta
- Proton Pump Inhibitors
- Crosses the placenta
- FDA Category B as a class including Esomeprazole (Nexium), Rabeprazole (Aciphex) and Lansoprazole (Prevacide)
- FDA Category C for Omeprazole (Prilosec) based on animal studies
- However, appears safe in pregnancy and is best studied of the PPI agents
- Aluminum hydroxide
- Pregnancy risk class is unknown, but appears safe in pregnancy
- Neurotoxicity risk at high dose
- Calcium Carbonate
- Pregnancy risk class is unknown, but appears safe in pregnancy
- First choice agent of the Antacids in pregnancy
- Crosses the placenta
- Risk of Milk-Alkali Syndrome at high dose
- Magnesium Hydroxide (or Magnesium carbonate)
- Pregnancy risk class is unknown, but appears safe in pregnancy
- Cimetidine (Tagamet)
- Anti-gas agents
- Simethicone
- FDA Category B
- Not absorbed and does not cross the placenta, so considered safe in pregnancy
- Simethicone
- Anti-Diarrheals
- Bismuth Subsalicylate (Pepto-Bismol)
- FDA Category C
- Avoid in pregnancy (especially second and third trimester due to Aspirin component)
- Loperamide (Imodium)
- FDA Category C
- Possible associations with cardiovascular defects
- Bismuth Subsalicylate (Pepto-Bismol)
-
Laxatives
- Mineral Oil
- FDA Category C
- Not absorbed (and does not cross the placenta)
- Avoid in pregnancy
- Risk of fat soluble Vitamin Decreased absorption (risk of neonatal Coagulopathy and bleeding complications)
- Castor Oil
- FDA Category X (absolutely contraindicated in pregnancy)
- Avoid in pregnancy due to risks to both mother and child
- Polyethylene Glycol 3350 (Miralax)
- FDA Category C
- Preferred Laxative for Constipation in Pregnancy
- Mineral Oil
VI. Preparations: Herbals
- Herbal agents that appear safe in pregnancy
- Echinacea
- Glucosamine
- Used for Joint Pain
- Ginger
- Appears effective for Morning Sickness
- Appears safe in pregnancy
- Early reports of Spontaneous Abortion and Preterm Labor were not found in larger trials
- Herbal agents that may result in Miscarriage via uterine stimulation (avoid)
- Mugwort
- Blue Cohosh
- Black Cohosh
- Goldenseal
- Juniper berry
- Chaste berry
- Rue
- Pennyroyal oil
- Herbal agents that are considered unsafe in pregnancy (avoid)
- St. John's Wort
- Lack of safety data
- Feverfew
- Inhibits Platelet aggregation
- Inhibits prostglandin production
- Ephedra
- Anencephaly risk
- Transposition of the Great Vessels risk
- Aortic Stenosis risk
- St. John's Wort
VII. Preparations: Topical Dermatologic Preparations
-
Topical Antifungal agents
- Topical Imidazoles (Miconazole, Clotrimazole)
- Absorption varies depending on concentration
- Well studied and appear safe in pregnancy
- Topical Nystatin
- Minimal absorption
- Well studied and appears safe in pregnancy
- Topical Terbinafine (Lamisil)
- Topical Terbinafine has not been studied, but oral Terbinafine is FDA Catetegory B
- Topical Imidazoles (Miconazole, Clotrimazole)
-
Topical Corticosteroids
- Hydrocortisone 1%
- Absorption varies to a maximum of 7%
- Appears safe in pregnancy, but limit to smallest area of needed application, and shortest duration of use
- Hydrocortisone 1%
-
Topical Antibiotics
- Topical Bacitracin
- Appears safe in pregnancy
- Topical Bacitracin
- Topical acne agents
- Topical Benzoyl Peroxide
- Appears safe in pregnancy (despite low levels of absorption up to 5%)
- Topical Benzoyl Peroxide
VIII. References
- Briggs (2008) Drugs in Pregnancy and Lactation, Lippincott Williams and Wilkins, Philadelphia, PA
- Servey (2014) Am Fam Physician 90(8): 548-55 [PubMed]